Sinsin Pharmaceutical Co. Ltd (002800) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinsin Pharmaceutical Co. Ltd (002800) has a cash flow conversion efficiency ratio of 0.066x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.70 Billion ≈ $3.18 Million USD) by net assets (₩71.01 Billion ≈ $48.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sinsin Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sinsin Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Sinsin Pharmaceutical Co. Ltd carry for a breakdown of total debt and financial obligations.
Sinsin Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinsin Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BioSmart Co.Ltd
KQ:038460
|
0.042x |
|
Yenher Holdings Bhd
KLSE:5300
|
0.028x |
|
Roscan Gold Corp
V:ROS
|
0.162x |
|
Astino Bhd
KLSE:7162
|
0.037x |
|
Diatreme Resources Ltd
AU:DRX
|
-0.003x |
|
James Bay Minerals Ltd
AU:JBY
|
N/A |
|
Kingfisher PLC
LSE:KGF
|
0.077x |
|
Oncoinvent ASA
OL:KLDVK
|
0.013x |
Annual Cash Flow Conversion Efficiency for Sinsin Pharmaceutical Co. Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sinsin Pharmaceutical Co. Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Sinsin Pharmaceutical Co. Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩65.87 Billion ≈ $44.64 Million |
₩5.94 Billion ≈ $4.03 Million |
0.090x | +42.55% |
| 2023-12-31 | ₩62.09 Billion ≈ $42.08 Million |
₩3.93 Billion ≈ $2.66 Million |
0.063x | -30.80% |
| 2022-12-31 | ₩59.70 Billion ≈ $40.46 Million |
₩5.46 Billion ≈ $3.70 Million |
0.091x | +21570.98% |
| 2021-12-31 | ₩54.93 Billion ≈ $37.22 Million |
₩23.18 Million ≈ $15.71K |
0.000x | -98.73% |
| 2020-12-31 | ₩56.20 Billion ≈ $38.08 Million |
₩1.87 Billion ≈ $1.26 Million |
0.033x | +141.52% |
| 2019-12-31 | ₩56.36 Billion ≈ $38.20 Million |
₩-4.51 Billion ≈ $-3.05 Million |
-0.080x | -663.11% |
| 2018-12-31 | ₩54.54 Billion ≈ $36.96 Million |
₩774.24 Million ≈ $524.69K |
0.014x | -83.80% |
| 2017-12-31 | ₩52.12 Billion ≈ $35.32 Million |
₩4.57 Billion ≈ $3.10 Million |
0.088x | +8.00% |
| 2016-12-31 | ₩34.43 Billion ≈ $23.33 Million |
₩2.79 Billion ≈ $1.89 Million |
0.081x | -- |
About Sinsin Pharmaceutical Co. Ltd
Sinsin Pharmaceutical Co., Ltd manufactures and sells pharmaceutical products in South Korea. It offers various medicinal products, such as plaster, aerosol, topical liquid, emollient, hygiene, and ointment products, as well as adhesive bandages, mosquito repellents, anti-perspirants, cooling sheets, bruise treatment creams, and other products. The company also develops transdermal drug delivery … Read more